Nevin Hammam1, Michael Evans1, Esi Morgan2, Andreas Reimold3, Christine Anastasiou1, Julia L Kay1, Jinoos Yazdany1, Gabriela Schmajuk4. 1. University of California, San Francisco. 2. University of Cincinnati, Cincinnati, Ohio. 3. Dallas Veterans Affairs Medical Center and University of Texas Southwestern University Medical Center, Dallas, Texas. 4. University of California, San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California.
Abstract
OBJECTIVE: Sarcoidosis is often treated with glucocorticoids, although the use of biologics is growing. Prescribing patterns for biologics for patients with sarcoidosis in US rheumatology practices have never been examined. Given that there are no steroid-sparing US Food and Drug Administration-approved therapies for sarcoidosis, we sought to characterize the real-world treatment of sarcoidosis and to assess practice-level variation in prescribing patterns. METHODS: We conducted an observational study of patients with sarcoidosis using data from the Rheumatology Informatics System for Effectiveness (RISE) registry (2014-2018). The RISE registry represents an estimated 32% of the US clinical rheumatology workforce. Adult patients with ≥2 codes for sarcoidosis ≥30 days apart were included. We examined sarcoidosis-specific medication use at any time during the study period. Data were analyzed at the practice level. RESULTS: A total of 3,276 patients with sarcoidosis from 184 practices were included. Of those patients, 75.1% were women, with a mean age of 59.0 ± 12.5 years; 48.3% were White and 27.6% were Black. Overall, 59.3% of patients were prescribed glucocorticoids, and 24.7% received prolonged glucocorticoid therapy (≥10 mg/day for ≥90 days). In all, 12.1% received a biologic or targeted synthetic disease-modifying antirheumatic drug (tsDMARD), most commonly tumor necrosis factor inhibitors. There was wide practice-level variation among 31 practices with ≥30 patients with sarcoidosis; biologic use ranged from 15.6% to 69.2%. Infliximab represented the most common biologic prescribed. CONCLUSION: In a large sample of US rheumatology practices, 12.1% of patients with sarcoidosis received biologics or tsDMARDs. We found high variability in biologic use across practices. The significant use of long-term glucocorticoids suggests unmet therapeutic needs in this patient population.
OBJECTIVE: Sarcoidosis is often treated with glucocorticoids, although the use of biologics is growing. Prescribing patterns for biologics for patients with sarcoidosis in US rheumatology practices have never been examined. Given that there are no steroid-sparing US Food and Drug Administration-approved therapies for sarcoidosis, we sought to characterize the real-world treatment of sarcoidosis and to assess practice-level variation in prescribing patterns. METHODS: We conducted an observational study of patients with sarcoidosis using data from the Rheumatology Informatics System for Effectiveness (RISE) registry (2014-2018). The RISE registry represents an estimated 32% of the US clinical rheumatology workforce. Adult patients with ≥2 codes for sarcoidosis ≥30 days apart were included. We examined sarcoidosis-specific medication use at any time during the study period. Data were analyzed at the practice level. RESULTS: A total of 3,276 patients with sarcoidosis from 184 practices were included. Of those patients, 75.1% were women, with a mean age of 59.0 ± 12.5 years; 48.3% were White and 27.6% were Black. Overall, 59.3% of patients were prescribed glucocorticoids, and 24.7% received prolonged glucocorticoid therapy (≥10 mg/day for ≥90 days). In all, 12.1% received a biologic or targeted synthetic disease-modifying antirheumatic drug (tsDMARD), most commonly tumor necrosis factor inhibitors. There was wide practice-level variation among 31 practices with ≥30 patients with sarcoidosis; biologic use ranged from 15.6% to 69.2%. Infliximab represented the most common biologic prescribed. CONCLUSION: In a large sample of US rheumatology practices, 12.1% of patients with sarcoidosis received biologics or tsDMARDs. We found high variability in biologic use across practices. The significant use of long-term glucocorticoids suggests unmet therapeutic needs in this patient population.
Authors: Patompong Ungprasert; Eva M Carmona; James P Utz; Jay H Ryu; Cynthia S Crowson; Eric L Matteson Journal: Mayo Clin Proc Date: 2015-12-22 Impact factor: 7.616
Authors: Jinoos Yazdany; Nick Bansback; Megan Clowse; Deborah Collier; Karen Law; Katherine P Liao; Kaleb Michaud; Esi M Morgan; James C Oates; Catalina Orozco; Andreas Reimold; Julia F Simard; Rachel Myslinski; Salahuddin Kazi Journal: Arthritis Care Res (Hoboken) Date: 2016-12 Impact factor: 4.794
Authors: Robert P Baughman; Shelli Field; Ulrich Costabel; Ronald G Crystal; Daniel A Culver; Marjolein Drent; Marc A Judson; Gerhard Wolff Journal: Ann Am Thorac Soc Date: 2016-08
Authors: Marc A Judson; Robert P Baughman; Ulrich Costabel; Marjolein Drent; Kevin F Gibson; Ganesh Raghu; Hidenobu Shigemitsu; Joseph B Barney; Daniel A Culver; Nabeel Y Hamzeh; Marlies S Wijsenbeek; Carlo Albera; Isham Huizar; Prasheen Agarwal; Carrie Brodmerkel; Rosemary Watt; Elliot S Barnathan Journal: Eur Respir J Date: 2014-07-17 Impact factor: 16.671
Authors: Nevin Hammam; Jing Li; Michael Evans; Julia L Kay; Zara Izadi; Christine Anastasiou; Milena A Gianfrancesco; Jinoos Yazdany; Gabriela Schmajuk Journal: Arthritis Res Ther Date: 2021-08-30 Impact factor: 5.606